AuthorisedTherapeutic exploratory (Phase II)Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

This study is testing a new treatment called Telisotuzumab Adizutecan. It's for adults whose solid tumours, which are either locally advanced (meaning they've spread a bit in the nearby area) or have spread to other parts of the body (metastatic), show a specific genetic change known as 'MET amplification'. This change means the cancer cells have too many copies of a particular gene. The main goal of the study is to see if this new drug can shrink the tumours. Researchers will also be looking at how long the treatment keeps the cancer from growing, how long the positive effects last, and overall survival rates. This is a Phase 2 study, which means it's still in the earlier stages of human testing, focusing on safety and how well the treatment works.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

AbbVie Deutschland GmbH & Co. KG

Enrolment target

Start

18 May 2026

Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

What is this study about?

This study is a clinical trial, which means it's a carefully planned medical research study involving people. Its main purpose is to test a new medicine called Telisotuzumab Adizutecan. This drug is intended for adults who have solid cancers – cancer that forms a lump – which are either quite advanced in the area where they started, or have spread to other parts of the body.

What makes this study special is that it's for cancers that have a particular genetic change. This change is called 'MET amplification,' which means the cancer cells have too many copies of a specific gene. Scientists believe that targeting this genetic change might be an effective way to treat these specific cancers.

The main goal is to see if Telisotuzumab Adizutecan can make tumours shrink. Beyond that, the researchers will also be checking how long the cancer stays under control without growing, how long any positive effects of the treatment last, and what impact it has on how long people live. This is an important step in developing new treatments for challenging cancers.

Key takeaways

This study is testing a new drug for specific advanced solid cancers.
It's for cancers with a genetic change called 'MET amplification'.
The main aim is to see if the drug can shrink tumours and slow cancer growth.
Participants must be 18 or older.
It's an early-stage study (Phase 2) looking at safety and effectiveness.
Participation involves regular check-ups and monitoring.

Who may be eligible?

To join this study, you need to be an adult, aged 18 or over. This study is open to both men and women.

The most important criteria relate to your cancer. You must have a 'solid tumour', which means a cancer that forms a mass rather than, for example, a blood cancer. This cancer should also be considered either 'locally advanced' (meaning it has grown significantly in its original area but hasn't spread widely) or 'metastatic' (meaning it has spread to other parts of your body).

Crucially, your cancer must also show a specific genetic change called 'MET amplification'. This change will be identified through special tests on your cancer cells. The study is specifically designed for people whose cancers have this particular characteristic.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a solid tumour (not a blood cancer)?
Has your cancer been identified as 'locally advanced' or 'metastatic'?
Have tests shown that your cancer has 'MET amplification'?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would receive the new drug, Telisotuzumab Adizutecan, as part of your treatment. The study would involve a series of visits to the clinic for medical check-ups, blood tests, and scans (like CT or MRI) to carefully monitor your health and how your cancer is responding to the treatment. These assessments are crucial for the researchers to understand the drug's effects.

The exact number and timing of visits would be explained in detail by the study team, but generally, clinical trials involve regular appointments. You would also have follow-up visits after your treatment period to continue monitoring your health. The total duration of your participation could vary, depending on how long you respond to the treatment and the study's follow-up plan, but the team will provide a clear timeline.

Potential risks and benefits

Taking part in this study might offer a chance to try a new treatment that isn't widely available yet, which could potentially help control your cancer. However, like all medicines, Telisotuzumab Adizutecan might cause side effects, some of which could be serious. The research team will explain all known or potential risks in detail, and you'll be closely monitored throughout the study. Remember, joining a clinical trial is always voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (3)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Spain
—
Unverified
France
—
Unverified
Denmark

Common questions

What does 'MET amplification' mean?

It means your cancer cells have too many copies of a particular gene called MET. This can sometimes make cancers grow faster.

Is Telisotuzumab Adizutecan a chemotherapy drug?

It's a type of targeted therapy, which is different from traditional chemotherapy. Targeted therapies are designed to attack specific features of cancer cells, like MET amplification, often with different side effects.

What is a 'Phase 2' study?

Phase 2 studies are an early stage of research. They look at how safe a new drug is and how well it works in a small group of people, after it's been shown to be safe in healthy volunteers.

How long will I be on the study drug?

The duration of your treatment will depend on how you respond to the drug and if you experience any side effects. The study team will discuss this with you.

What does 'locally advanced' or 'metastatic' solid tumours mean?

'Locally advanced' means the cancer has grown in the area where it started but hasn't spread far. 'Metastatic' means the cancer has spread from its original site to other parts of the body.